Press Latest Release CSL News Mon, 11 Dec 2017 00:00:00 -0500 CSL Behring Australia and National Blood Authority Sign New National Fractionation Agreement for Australia thumbnail CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and secure supply of plasma-derived therapies manufactured in Australia. 1252906298697 Thu, 07 Dec 2017 00:00:00 -0500 Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and Creates Victorian Jobs thumbnail Leading global biotherapeutics company CSL Limited (ASX:CSL), today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP. 1252906279001 Tue, 05 Dec 2017 00:00:00 -0500 CSL and Vitaeris Announce Strategic Partnership with Option to Acquire thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection. 1252906258521 Tue, 05 Dec 2017 00:00:00 -0500 CSL Confirms Phase 3 Clinical Trial of New Therapy for Heart Attack Survivors thumbnail Global biotherapeutics leader CSL (ASX:CSL) today announced that it will proceed with a Phase 3 clinical trial for CSL112, the company’s novel therapy for reduction of early recurrent cardiovascular events in heart attack survivors. The decision has been made subject to final agreement with the US Food and Drug Administration (FDA) on important elements of the study design. 1252906249142 Tue, 17 Oct 2017 00:00:00 -0500 Australian Scientists awarded $2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease thumbnail Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance understanding of what really causes our arteries to clog. 1252906010923 Thu, 05 Oct 2017 00:00:00 -0500 New Debt Facilities [thumbnail] CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 4 October 2017 it closed a new USD700 million private placement in the U.S. The private placement was foreshadowed in CSL’s full year announcement in August 2017. 1252905959272 Mon, 28 Aug 2017 00:00:00 -0500 CSL Behring Acquires Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform thumbnail CSL Limited today announced that CSL Behring has agreed to acquire Calimmune, Inc., a US biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California, USA and Sydney, New South Wales, Australia for an upfront payment of $91 million. 1252905759425 Wed, 16 Aug 2017 00:00:00 -0500 Full Year Result 2017 [thumbnail] CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $1,337 million for the 12 months ended 30 June 2017. 1252905508664 Thu, 03 Aug 2017 00:00:00 -0500 CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator [thumbnail] CSL Limited today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. 1252905510741 Mon, 10 Jul 2017 00:00:00 -0500 CSL Response to Patent Infringement Complaint thumbnail CSL Limited has become aware that Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the International Trade Commission. 1252905315629 Fri, 23 Jun 2017 00:00:00 -0500 HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) FDA Approval thumbnail CSL today announced that the U.S. Food and Drug Administration (FDA) has approved CSL Behring’s HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. 1252905126372 Tue, 13 Jun 2017 00:00:00 -0500 CSL to acquire majority stake in Chinese plasma fractionatorWuhan Zhong Yuan Rui De Biologicals Products thumbnail CSL to acquire an 80 per cent stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (“Ruide”) in China for US$352 million. 1252904953475 Thu, 01 Jun 2017 00:00:00 -0500 Applications Open for CSL Centenary Fellowship Program$1.25 Million Funding Available to Australia’s Best and Brightest Biomedical Researchers thumbnail Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical research. 1252904808110 Wed, 12 Apr 2017 00:00:00 -0500 CSL Response to Patent Complaint thumbnail CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims. 1252904542423 Wed, 15 Feb 2017 00:00:00 -0500 Half Year Result 20171 thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP). 1252904041419 Fri, 10 Feb 2017 00:00:00 -0500 Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease thumbnail Melbourne, 10 February, 2017 04.00AM AEDT: An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes. 1252904056688 Thu, 19 Jan 2017 09:00:00 -0500 FY2017 profit upgrade thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance, CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016. 1252903872987 Thu, 05 Jan 2017 00:00:00 -0500 Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors thumbnail Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017. 1252903829512